Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors.

摘要: Abstract Background Depression and anxiety are common disorders have substantially overlapping symptom complexes. Not surprisingly, treatment approaches similar for both conditions with the selective serotonin reuptake inhibitors (SSRIs) as initial therapy of choice. However, after first line treatments been deployed, residual symptoms often problematic. Augmentation strategies to address these difficulties an area active investigation. This study assessed aripiprazole adjunctive SSRIs patients persistent complicating a depression or disorder. Methods Ten who had receiving at least 6 weeks, but still clinically significant symptoms, were enrolled in open label, flexibly-dosed aripiprazole. Clinical status was Hamilton Anxiety Rating Scale (HAM-A), Montgomery Asberg (MADRS), Sheehan Disability (SDS). Results Eighty percent subjects greater than 50% reduction on outcome measures by week 2 therapy, continued further decrements throughout course study. Conclusions The results this trial provide preliminary evidence that may be effective individuals depression. More rigorous double-blind studies warranted confirm elucidate potential role conditions.